Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

References

• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–6. doi: 10.1111/jdv.18345.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: 10.1111/jdv.18429.
   PubMed Web of Science ®Google Scholar
• D’Erme AM, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:1473–1480. doi: 10.2147/DDDT.S113192.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Ferrucci S, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2020;3:1–4.
   Google Scholar
• de Wijs LEM, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418–426. doi: 10.1111/bjd.18749.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, Bakker D, Drylewicz J, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. 2022;77(11):3398–3407. doi: 10.1111/all.15439.
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Fabbrocini G, et al. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis. Dermatol Ther. 2022;35(12):e15933. doi: 10.1111/dth.15933.
   PubMed Web of Science ®Google Scholar
• Jendoubi F, Shourik J, Seneschal J, et al. Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a french multicentre retrospective cohort study. Br J Dermatol. 2022;187(4):602–603. doi: 10.1111/bjd.21628.
   PubMed Web of Science ®Google Scholar
• Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–143. doi: 10.1001/jamadermatol.2019.3617.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, Boesjes CM, Loman L, et al. Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023;ljad159. doi: 10.1093/bjd/ljad159.
   PubMedGoogle Scholar
• Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88. doi: 10.18176/jiaci.0138.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39–45. doi: 10.1016/j.jaad.2020.03.049.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Di Nardo L, Talamonti M, et al. Patients withdrawing dupilumab monotherapy for COVID-19-Related reasons showed similar disease course compared with patients continuing dupilumab therapy. Dermatitis. 2022;33(3):e25–e29. doi: 10.1097/DER.0000000000000814.
   PubMed Web of Science ®Google Scholar
• Park K, Mori T, Nakamura M, et al. Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. Eur J Dermatol. 2011;21(1):135–136. doi: 10.1684/ejd.2010.1196.
   PubMed Web of Science ®Google Scholar
• Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5):990–996. doi: 10.1111/j.1365-2133.2011.10498.x.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180–1190. doi: 10.1038/s41591-023-02320-9.
   PubMed Web of Science ®Google Scholar